Sorrento Therapeutics (SRNE) 5.10 $SRNE
Sorrento Therapeutics to Present at Two Healthcare Conferences
PR Newswire - Fri Sep 05, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
Sorrento secures NIH grant to advance WISP1 in the Idiopathic Pulmonary Fibrosis programme
M2 - Wed Aug 27, 6:07AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Tuesday the receipt of a Small Business Innovation Research (SBIR) Phase 1 grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF).
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire - Tue Aug 26, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
PR Newswire - Mon Aug 18, 6:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors
PR Newswire - Fri Aug 08, 4:00PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors.
Sorrento condoles sudden death of its EVP Amar Singh
M2 - Fri Aug 01, 8:06AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) disclosed on Thursday the demise of Amar Singh, chief business officer and executive vice president, suddenly and unexpectedly on 30 July 2014.
Sorrento Announces the Unexpected Death of its Chief Business Officer
PR Newswire - Thu Jul 31, 4:38PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
Sorrento wins National Institutes of Health's grant for development of small molecule Myc inhibitor
M2 - Tue Jul 22, 8:30AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the receipt of the non-dilutive funding for the development of the small molecule inhibitor targeting the important oncogenic transcription factor Myc.
Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates
PR Newswire - Tue Jul 01, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB® library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates
PR Newswire - Wed Jun 25, 7:45AM CDT
Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive research fees, up-front payment, milestone payments and royalties on future net sales. Sorrento has the potential to receive up to $50 million upon successful attainment of key milestones.
Sorrento Therapeutics Announces Confidential Submission of Draft Registration Statement for Initial Public Offering (IPO) of its Wholly-owned Subsidiary Ark Animal Health with the SEC
PR Newswire - Mon Jun 23, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has submitted a draft registration statement on Form S-1 on a confidential basis with the U.S. Securities and Exchange Commission for a possible initial public offering of shares of common stock of its wholly-owned subsidiary, Ark Animal Health, Inc. ("Ark"
. The number of shares to be offered and the price range for the offering have not yet been determined.
Sorrento to Present at BIO Business Forum
PR Newswire - Fri Jun 20, 2:15PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" , a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the BIO Business Forum, taking place June 23rd-26th, 2014 in San Diego, CA. The presentation will take place in the Imperial Beach Presentation Room on Tuesday, June 24 at 2:45 pm PDT.
Sorrento's underwriters exercise 714,750 common shares in over-allotment option
M2 - Fri Jun 13, 5:16AM CDT
Oncology company Sorrento Therapeutics (NasdaqCM:SRNE) said on Thursday that the underwriters of its public offering have exercised in full their option to purchase an additional 714,750 shares of common stock at the same offering price to cover over-allotments.
Sorrento Announces Underwriters' Exercise of Over-Allotment Option
PR Newswire - Thu Jun 12, 7:30PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company" , a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that the underwriters of its previously announced underwritten public offering of 4,765,000 shares of its common stock have exercised in full their option to purchase an additional 714,750 shares of common stock from the Company at $5.25 per share to cover over-allotments, bringing total gross proceeds from this offering to approximately $28,768,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering of these additional shares is expected to close on or about June 16th, 2014, subject to customary closing conditions.
Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane
PR Newswire - Mon Mar 31, 8:31PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer.
Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications
PR Newswire - Tue Mar 25, 6:47AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, initially devoted to developing resiniferatoxin (RTX) for multiple veterinary health applications and vaccines against recurrent staphylococcal infections.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
PR Newswire - Tue Mar 11, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors.
Sorrento Therapeutics to Present at Two Healthcare Conferences
PR Newswire - Fri Sep 05, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
Sorrento secures NIH grant to advance WISP1 in the Idiopathic Pulmonary Fibrosis programme
M2 - Wed Aug 27, 6:07AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Tuesday the receipt of a Small Business Innovation Research (SBIR) Phase 1 grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF).
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire - Tue Aug 26, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
PR Newswire - Mon Aug 18, 6:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors
PR Newswire - Fri Aug 08, 4:00PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors.
Sorrento condoles sudden death of its EVP Amar Singh
M2 - Fri Aug 01, 8:06AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) disclosed on Thursday the demise of Amar Singh, chief business officer and executive vice president, suddenly and unexpectedly on 30 July 2014.
Sorrento Announces the Unexpected Death of its Chief Business Officer
PR Newswire - Thu Jul 31, 4:38PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
Sorrento wins National Institutes of Health's grant for development of small molecule Myc inhibitor
M2 - Tue Jul 22, 8:30AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the receipt of the non-dilutive funding for the development of the small molecule inhibitor targeting the important oncogenic transcription factor Myc.
Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates
PR Newswire - Tue Jul 01, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB® library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates
PR Newswire - Wed Jun 25, 7:45AM CDT
Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive research fees, up-front payment, milestone payments and royalties on future net sales. Sorrento has the potential to receive up to $50 million upon successful attainment of key milestones.
Sorrento Therapeutics Announces Confidential Submission of Draft Registration Statement for Initial Public Offering (IPO) of its Wholly-owned Subsidiary Ark Animal Health with the SEC
PR Newswire - Mon Jun 23, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has submitted a draft registration statement on Form S-1 on a confidential basis with the U.S. Securities and Exchange Commission for a possible initial public offering of shares of common stock of its wholly-owned subsidiary, Ark Animal Health, Inc. ("Ark"
. The number of shares to be offered and the price range for the offering have not yet been determined. Sorrento to Present at BIO Business Forum
PR Newswire - Fri Jun 20, 2:15PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"
, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the BIO Business Forum, taking place June 23rd-26th, 2014 in San Diego, CA. The presentation will take place in the Imperial Beach Presentation Room on Tuesday, June 24 at 2:45 pm PDT. Sorrento's underwriters exercise 714,750 common shares in over-allotment option
M2 - Fri Jun 13, 5:16AM CDT
Oncology company Sorrento Therapeutics (NasdaqCM:SRNE) said on Thursday that the underwriters of its public offering have exercised in full their option to purchase an additional 714,750 shares of common stock at the same offering price to cover over-allotments.
Sorrento Announces Underwriters' Exercise of Over-Allotment Option
PR Newswire - Thu Jun 12, 7:30PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"
, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that the underwriters of its previously announced underwritten public offering of 4,765,000 shares of its common stock have exercised in full their option to purchase an additional 714,750 shares of common stock from the Company at $5.25 per share to cover over-allotments, bringing total gross proceeds from this offering to approximately $28,768,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering of these additional shares is expected to close on or about June 16th, 2014, subject to customary closing conditions. Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane
PR Newswire - Mon Mar 31, 8:31PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer.
Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications
PR Newswire - Tue Mar 25, 6:47AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, initially devoted to developing resiniferatoxin (RTX) for multiple veterinary health applications and vaccines against recurrent staphylococcal infections.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
PR Newswire - Tue Mar 11, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors.
